Email: jwangliu@163.com

Introduction: 
I was born in Anhui, China and I received BS degree from Anhui University of Chinese Medicine in 2017. I'm currently a PhD graduatein the research group of Professor Li at East China University of Science and Technology and major in computer aided drug design.

Education Background:
2017-2023, Ph.D., Pharmacy, East China University Of Science And Technology.
2013-2017, B.E., Pharmaceutical Preparations, Anhui University of traditional Chinese Medicine.

Publication:

1. Jie Wang^†, Zihao Shen^†, Yichen Liao, Zhen Yuan, Shiliang Li, Gaoqi He, Man Lan, Xuhong Qian, Kai Zhang*, Honglin Li*. Multi-Modal chemical information reconstruction from images and texts for exploring the near-drug space. Briefings Bioinf., 2022: bbac461.

2. Dou Dou^†, Jie Wang^†, Yunjin Qiao^†, Gulinuer Wumaier^†, Wenjie Sha^†, Wenjie Li, Wenyi Mei, Tingyuan Yang, Chen Zhang, Huan He, Caolin Wang, Linna Chu, Baihui Sun, Rongrong Su, Xiangyu Ma, Mengdie Gong, Lijuan Xie, Yanyan Diao, Lili Zhu, Zhenjiang Zhao, Zhuo Chen*, Yufang Xu*, Shengqing Li*, and Honglin Li*. Discovery and optimization of 4-anilinoquinazoline derivatives that spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. Eur. J. Med. Chem., 2022.

3. Huan He^†, Qi Liu^†, Lu Chen^†, Jie Wang^†, Yuan Yuan¹, Honglin Li¹, Xuhong Qian¹, Zhenjiang Zhao*, Zhuo Chen*. Design, synthesis and biological evaluation of Pteridine-7(8H)-one Derivatives as potent and selective CDK4/6 inhibitors. Bioorg. Med. Chem. Lett., 2022. 76: 128991.

4. Tong Zhao^†, Jie Wang^†, Yidi Chen, Shan Wang, Jian Lu, Jianlu Lv, Shiliang Li, Jiaying Wang, Minyi Qian*, Honglin Li*, Xu Shen*. Antiallergic drug Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist. Metabolism, 2021. 119 : 154771.

5. Disha Wang, Wenjun Liu, Zihao Shen, Lei Jiang, Jie Wang, Shiliang Li*, Honglin Li*. Deep Learning Based Drug Metabolites Prediction. Front. Pharmacol., 2020. 10 : 1586.

6. Zhicheng Su^†, Tingyuan Yang^†, Jie Wang^†, Mengzhen Lai, Linjiang Tong, Gulinuer Wumaier, Zhuo Chen*, Shengqing Li, Honglin Li, Hua Xie*, Zhenjiang Zhao*. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. Bioorg. Med. Chem. Lett., 2020. 30(16) : 127327.

7. Jie Wang, Shiliang Li, Honglin Li*. Drug design of "undruggable" targets. Chin. J. Chem., 2019. 37 : 501-512.